CMS NCD 344 Autologous Cellular Immunotherapy (Sipuleucel-T) Coverage Policy: What Billing Teams Need to Know in 2026

The Centers for Medicare & Medicaid Services has modified National Coverage Determination 344, which governs Medicare coverage of autologous cellular immunotherapy treatment—specifically sipuleucel-T (PROVENGE®)—for prostate cancer. This update affects urology, oncology, and infusion practices billing for this unique, patient-specific immunotherapy. Here's everything your revenue cycle team needs to act on this change.

What CMS NCD 344 Covers for Sipuleucel-T (PROVENGE®)

NCD 344 establishes Medicare's national coverage position for sipuleucel-T, the first FDA-approved immunotherapy for prostate cancer. CMS concluded that evidence is adequate to determine this treatment improves health outcomes for a specific Medicare beneficiary population, making it "reasonable and necessary" under Section 1862(a)(1)(A) of the Social Security Act.

Coverage is effective for services performed on or after June 30, 2011, and this 2026 modification carries forward and refines that framework. The policy applies across two Medicare benefit categories: Outpatient Hospital Services Incident to a Physician's Service and Physicians' Services.

CMS Medical Necessity Criteria: Who Qualifies Under NCD 344

CMS coverage of sipuleucel-T is tightly scoped to the FDA-approved on-label indication. To meet medical necessity under this NCD, the patient must have:

This is not a broad coverage determination. Patients with symptomatic disease, non-metastatic castration-resistant prostate cancer, or earlier-stage disease do not meet the nationally covered indication. Documentation in the medical record must support each of these three criteria before the treatment course begins.

How Sipuleucel-T Works — and Why the Billing Process Is Unique

Understanding the clinical workflow is essential to billing it correctly. Sipuleucel-T is not a pre-manufactured drug dispensed from a pharmacy. It is individually produced for each patient using his own white blood cells, which makes the billing sequence multi-step and time-sensitive.

The treatment process unfolds as follows:

1. Leukapheresis — The patient's white blood cells are collected via apheresis
2. Laboratory processing — White blood cells are exposed to PA2024 (prostatic acid phosphatase linked with GM-CSF) to activate an immune response targeting prostate cancer cells
3. Infusion — The treated cells are returned to the patient intravenously

The FDA-approved dosing is three infusions, each administered approximately two weeks apart, over a total treatment period of four weeks. Each dose must contain a minimum of 40 million activated white blood cells, though CMS acknowledges there is "high inherent variability" in yield between leukapheresis sessions and between patients.

This variability matters for billing teams because a leukapheresis session that does not yield a viable dose may still be billed, but supporting documentation must be airtight.

Nationally Non-Covered Indications Under NCD 344

CMS lists no nationally non-covered indications in the current version of NCD 344. However, the coverage is limited strictly to the on-label FDA indication described above. Any off-label use—such as sipuleucel-T for non-prostate cancers or for patients who do not meet the castration-resistant metastatic criteria—would fall outside NCD 344's coverage and should not be billed as a covered Medicare service without additional Local Coverage Determination (LCD) support or a coverage determination through the Medicare appeals process.

Benefit Categories and Site-of-Service Considerations

NCD 344 covers sipuleucel-T under two benefit categories, and site-of-service coding must align accordingly:

• Outpatient Hospital Services Incident to a Physician's Service — For infusions administered in a hospital outpatient department
• Physicians' Services — For services rendered in a physician office or clinic setting

CMS notes this may not be an exhaustive list of applicable benefit categories. Check your Medicare Administrative Contractor (MAC) for any supplemental guidance on benefit category assignment in your region, particularly if your facility operates a hybrid outpatient oncology infusion center.

Affected Codes

The current version of NCD 344 does not list specific CPT or HCPCS codes within the policy document. Your billing team should reference the applicable HCPCS and CPT codes through your MAC's local guidance and the Medicare Claims Processing Manual. When this policy lists specific codes in a future version, PayerPolicy will update this post immediately.

No specific CPT, HCPCS, or ICD-10 codes are listed in the current NCD 344 policy document. Do not rely on assumed codes—confirm billing codes directly through your MAC or CMS's HCPCS code lookup tool before submitting claims.

What Your Billing Team Should Do